Why the study?
Do biofeedback therapies improve outcomes in patients with cardiovascular diseases?
Do biofeedback therapies improve outcomes in patients with cardiovascular diseases?
Biofeedback may serve as a useful nonpharmacologic adjunct in the management of various cardiovascular diseases.
Answers are grounded in this paper and cite their sources.
Biofeedback should not yet change cardiovascular practice; leaves open need for randomized trials to confirm utility.
Cardiovascular diseases impair the lives of millions of Americans each year. Researchers have studied a variety of nonpharmacologic interventions in an attempt to discover their use as therapies for these diseases. Various methods of biofeedback have shown promise in the treatment or management of several cardiovascular disorders. The literature relating to the use of biofeedback therapies for hypertension, cardiac arrhythmias, angina pectoris, cardiac ischemia, myocardial infarction, and Raynaud's phenomenon is reviewed. The number and types of studies in each of these areas vary widely, but research to date suggests that biofeedback could be a useful alternative or adjunct to more conventional forms of treatment. Further research to clarify the appropriate uses of biofeedback in the management of these disorders is recommended.
No takes yet. Share an insight, caveat, or question.
Kranitz et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: